You are here

Innovation Theaters Schedule

Exhibit Hall Booths #1638, 1703, 1722

Grab a bite and get informed at the Innovation Theater. Don’t miss out on participating in a non-CME informative lunch or snack break discussion about the latest clinical information as it relates to a specific disease state. Innovation Theater presentations are independently organized and are not an official part of the Internal Medicine Meeting 2016 education program.

Thursday, May 5

Morning Break - 10:30-11:15 a.m.
Innovation Theater 1 - Booth 1703

PRALUENT® (alirocumab) Injection: Efficacy, Safety & Tolerability with Two Different Dosing Regimens
Supported by Sanofi Regeneron

Morning Break - 10:30-11:15 a.m.
Innovation Theater 2 - Booth 1722
Hospital Discharge:  Transitions of Care for Patients with Diabetes
Supported by Sanofi

Discharging patients with diabetes from the hospital is a critical step in the transition of care. This presentation will review clinical data on Toujeo®, a long acting basal insulin indicated to improve glycemic control in patients with diabetes. Data on the pharmacology, efficacy, safety and case studies will be presented.

Charles F Shaefer, Jr, MD, FCCP, FACP
Augusta, Georgia

 

Lunch - 1-1:45 p.m.
Innovation Theater 1 - Booth 1703

HARVONI—Changing What Is Possible with a Breakthrough Treatment
Supported by Gilead Sciences

Lunch - 1-1:45 p.m.
Innovation Theater 2 - Booth 1722

Are You Managing LDL-Related CVD Risk with a Reliable Measure of LDL?
Supported by LabCorp

Theater participants will understand readily available low-density lipoprotein particle (LDL-P) measures and their clinical utility for at-risk patients, suggested management strategies, and an overview of supporting data and guidelines to bring clarity to the confusion surrounding biomarkers and targets of therapy.

William C. Cromwell, MD
Burlington, North Carolina

Lunch - 1-1:45 p.m.
Innovation Theater  3 - Booth 1638

Influenza Immunization in Older Adults: Protecting a Vulnerable Population
Supported by Sanofi Pasteur

Influenza infection presents a substantial threat to the health of all older adults. Approximately 90% of influenza-related deaths occur in people 65 years of age and older despite a 67% vaccination rate for seniors against influenza. This presentation will explore strategies for disease prevention in the senior population and share pertinent data from clinical trials of influenza vaccines.

Carlos E. Picone, MD, FACP, FCCP
Washington, DC

 

Afternoon Break - 3:45-4:30 p.m.
Innovation Theater 1 - Booth 1703

Toujeo® (insulin glargine injection 300 Units/mL) A Once-Daily Basal Insulin:  Clinical Overview and Features
Supported by Sanofi

Toujeo (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin for adult patients with diabetes mellitus. The presentation will provide clinicians with an overview of Toujeo, including the pharmacologic profile and data from 4 EDITION clinical trials carried out in a range of adult patients with diabetes.

 

Friday, May 6

Morning Break - 10:30-11:15 a.m.
Innovation Theater  1 - Booth 1703
Pneumococcal Disease in Adults 65+: Keeping Vaccination in Focus

Supported by Pfizer

Morning Break - 10:30-11:15 a.m.
Innovation Theater 2 - Booth 1722

Repatha® (evolocumab): Product Overview
Supported by Amgen

Michael J. Bloch, MD, FACP, FASH, FSVM, FNLA
Reno, Nevada

 

Lunch - 1-1:45 p.m.
Innovation Theater 1 - Booth 1703
Thrombosis: AFib & DVT/PE - An Exploration in Risk Reduction

Supported by Janssen Pharmaceuticals, Inc.

This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

Pamela R. Kushner, MD, FAAFP
Irvine, California

Lunch - 1-1:45 p.m.
Innovation Theater 2 - Booth 1722
Targeted Strategies for Weight Regulation

Supported by Novo Nordisk

This presentation will review the complex and chronic nature of obesity and examine the benefits of effective weight management strategies. We will also discuss the clinical benefits of targeted appetite regulation via the glucagon-like peptide-1 (GLP-1) pathway.

Domenica M. Rubino, MD
Arlington, Virginia

Lunch - 1-1:45 p.m.
Innovation Theater 3 - Booth 1638
IBSchek: Quick, Reliable Blood Test for a Confident Diagnosis of IBS

Supported by Commonwealth Laboratories

IBSchek™ is the only quick and reliable blood test for a confident diagnosis of Irritable Bowel Syndrome (IBS). Our presenter, Mark Pimentel, MD, will discuss the pathophysiology of IBS as well as new approaches to diagnosing IBS. Dr. Pimentel will also review the rationale and data for IBSchek™. An interactive question and answer session will be available at the end of the presentation.

Brooks D Cash, MD
Mobile, Alabama

 

Afternoon Break - 3:45-4:30 p.m.
Innovation Theater 1 - Booth 1703
Evolution of Xifaxan® (rifaximin): A Clinical Overview of Advancement in Approved Indications

Supported by Salix Pharmaceuticals

Brooks D. Cash, MD
Mobile, Alabama

Ilan S. Weisberg, MD
New York, New York

 

 

 

 

Looking for materials from last year's meeting, or information on how to claim CME credit or MOC points?